Crossmark

FGF/FGFR1,2 targeting can attenuate lung parenchymal and vascular remodeling: an opportunity for drug repurposing against chronic lung disease and post COVID‐19 sequelae

Crossref DOI link: https://doi.org/10.1186/s42047-025-00202-7

Published Online: 2025-09-20

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kulshrestha, R.

Rani, M.

Dahiya, R.

Singh, A.

Doraiswamy, S.

Bharadwaj, S.

Batra, J.

Kumar, P.

Pandey, A.

Dinda, A. K.

Krishnan, R.

Mishra, A. K.
Funding

Funding for this research was provided by:

Department of Science and Technology (SB/SO/HS-0114/2013)
License Information

Text and Data Mining valid from 2025-09-20

Version of Record valid from 2025-09-20
More Information

Article History

Received: 3 October 2024

Accepted: 25 July 2025

First Online: 20 September 2025

Declarations

:

: Yes, I have the approval of the Institutional ethics committee for my project No-IAEC/46/2014 dated 25.11.14, VPCI/IAEC/2015/03 dated 21.10.15.

: Yes, I have the Consent for publication from all the co- authors.

: I hereby declare that there is no competing interest among the authors.

Document is current

Any future updates will be listed below